SIRONA BIOCHEM WKN: A0RM6R ISIN: CA82967M1005 Kürzel: ZSB Forum: Aktien Thema: Hauptdiskussion

Würde sagen der absolute focus ist jetzt aa und man scheint aus der vergangenheit zu lernen und holt sich Leute ins Boot die wissen was sie tun. Macht mir hoffnung

Das sind doch mal positive Nachrichten. Freut mich!

Und die Monica Alfaro Welling hat mal bei Allergan gearbeitet: "Prior to her consulting career, she held executive and management roles at Allergan, Novo Nordisk, and a start-up company."

Und linda pullan ist da auch irgendwie verwickelt

Wenn sie beim Botox launch geholfen hat, dann hat diese Frau sicher die richtigen Kontakte um Sirona zum Erfolg zu helfen!

Und schaut Mal auf die Homepage des Unternehmens, dann unter Team und dann Business development.😏😎

Sehr gut. Man geht zumindest professionell organisiert und aufgestellt in die Messe. Das kann ich nur begrüßen!!!

About Monica Alfaro Welling, MBA – Commercial/Business Development With over 30 years of experience in new product planning, strategic planning, portfolio analysis, market development and sales/marketing, business development of pharmaceuticals, biotechnology, and medical devices, Monica has had a unique career in the life science industry. She has been involved in every aspect of the development and commercialization process of early and late-stage technologies and new therapeutic applications. Monica has launched several disruptive technologies including BOTOX ® and been involved in a number of programs targeting the aesthetic market. Throughout her career, she has led development of commercial strategies including positioning, messaging, KOL development, reimbursement strategies and clinical studies to support positioning. In addition, her experience spans across a multitude of therapeutic areas including dermatology (clinical and aesthetics), oncology, ophthalmology, endocrinology, CNS, pain, addiction, back pain, and orphan diseases. Through her C-suite experience and consulting, Monica has been involved in fundraising (public and private) and licensing activities including profiling of potential strategics, outreach and defining deal terms. Prior to her consulting career, she held executive and management roles at Allergan, Novo Nordisk, and a start-up company. She has an MBA from Southern Danish University in Denmark, as well as a BS in Biology and a BA in Economics from the University of California, Irvine. About Atheln Inc. Atheln helps clients create and execute integrated pharma and biotech product development and commercialization strategies. With a global team of over 100 highly specialized, industry-seasoned experts Atheln’s team excel at risk identification and mitigation, while delivering phase appropriate and customized solutions that maximize value and increase the likelihood of success for our clients. For more information, please visit www.athelnbiomed.com.

Vancouver, British Columbia – May 25, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce it has contracted Atheln Inc. ("Atheln"), a leading US consulting firm, to bolster and facilitate Sirona's business activities. This strategic initiative comes at an opportune time, as Sirona prepares for the highly anticipated BIO International 2023 conference in Boston, where it will showcase its groundbreaking anti-aging compound, TFC-1326. Under the guidance of Monica Alfaro Welling, Atheln will spearhead the project team to ensure the success of Sirona's meetings during the conference. The primary focus of the contract is to meticulously prepare for the BIO International conference, where Sirona aims to establish valuable partnerships for the development and commercialization of TFC-1326. Recognizing the significance of these meetings, the collaboration with Atheln aims to maximize the probability of success. Sirona’s team has secured numerous meetings with organizations and companies that possess complementary resources, capabilities, and a strategic interest in partnerships. Sirona recognizes that effective communication, thorough preparation, and a clear value proposition significantly enhance the likelihood of finding suitable partners for TFC-1326 at the BIO International conference. Following the conclusion of the BIO conference, Sirona will continue to work with Atheln to extend its global outreach to companies that did not attend the event. By expanding efforts to establish valuable connections and collaborations, Sirona aims to forge strategic alliances and broaden the reach of its innovative solutions.

Wir schaffen es nie dauerhaft über 0,1 🙈

Frag sie doch bitte mal... Du hast doch Kontakt... Und als neuer CEO solltest du dich unverzüglich bewerben!!! So viel Herz für eine Company... 🙂

Howard, I am with you 😢😁

Angeblich sind sie ja in finalen Gesprächen. Würde mir so sehr wünschen das sirona übernommen wird und diese amateurhafte kac ke ein Ende findet. Jetzt hält Géraldine erstmal einen tollen Vortrag und im Anschluss vergrault howard die Interessenten in Einzelgespräche. Der Typ muss endlich weg aber dafür muss Kohle herbei. Würde gerne in einer Q&A thematisieren warum er eine Finanzierung macht bevor sie news raushauen. Das ist eine frechheit

Wann werden sie denn endlich die Homepage aktualisieren und das scheiß pet Thema rausnehmen? Mittlerweile ist es ja schon fast Vorsatz und Betrug an den shareholder was Sirona bei dem Thema treibt.

Ja, in Room 104C

Kann man da live zuhören?